Intercept Pharmaceuticals (NAS:ICPT) Cash Flow from Operations

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Intercept Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2023 was $-31.9 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Intercept Pharmaceuticals's depreciation, depletion and amortization for the three months ended in Mar. 2023 was $0.1 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Intercept Pharmaceuticals's change in working capital for the three months ended in Mar. 2023 was $-24.1 Mil. It means Intercept Pharmaceuticals's working capital declined by $24.1 Mil from Dec. 2022 to Mar. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Intercept Pharmaceuticals's cash flow from deferred tax for the three months ended in Mar. 2023 was $0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Intercept Pharmaceuticals's cash from discontinued operating Activities for the three months ended in Mar. 2023 was $-0.3 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Intercept Pharmaceuticals's asset impairment charge for the three months ended in Mar. 2023 was $0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Intercept Pharmaceuticals's stock based compensation for the three months ended in Mar. 2023 was $5.9 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Intercept Pharmaceuticals's cash flow from others for the three months ended in Mar. 2023 was $-1.3 Mil.

Intercept Pharmaceuticals Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.